Recently, Hepalink’s companies have been attracted by telecom fraud. In addition to the amount of fraud involving more than 90 million yuan attracting attention, many people are curious about how this company was defrauded and what its origins were.
An A-share listed company was defrauded of nearly 100 million yuan via electronic mail
On the 15th, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. issued an announcement stating that its wholly-owned subsidiary Techdow Pharma Italy SRL (referred to as “Tiandao Italy”) has recently encountered telecommunications fraud by criminal gangs, involving an amount of approximately 11.7 million euros (equivalent to approximately RMB 10,000). 91 million yuan).
The announcement stated that after the incident, the company reported the case to the local police as soon as possible, and the police have filed a case and carried out investigation and handling of the case. At the same time, the company fully cooperates with the police and strives to avoid losses as much as possible.
The company’s management has notified all directors, independent directors and the audit committee as soon as possible, and has initially determined that this is an accidental incident and confirmed that the company’s production and operations are operating normally. The management carefully reviewed this emergency incident and actively took measures to strengthen internal control management, improve standard governance, and enhance risk prevention awareness. The company’s management takes this matter seriously and has sent personnel to the subsidiary to handle the matter.
Because Hepalink did not disclose the details of how they were defrauded by electronic mail, many netizens were curious, “Is there any follow-up” and “This is the first time I have seen this method”…
The family behind the scenes emerges
According to Hepalink’s official website, Hepalink is a biopharmaceutical company that has completed transnational closed-loop layout in all aspects of the heparin industry chain. All of Hepalink’s enoxaparin sodium preparations are produced from Hepalink’s own heparin raw materials.
Tiandao Italy, which was involved in telecommunications fraud this time, is a wholly-owned subsidiary of Hepalink and is backed by Hepalink Group. An article on the Hepalink website in July 2023 shows that Tiandao Medicine has provided a total of 450 million enoxaparin sodium injections in Europe so far.
Tianyancha shows that Hepalink’s legal representative is Li Li, the largest shareholder Shenzhen Leren Technology Co., Ltd. holds 32.31% of Hepalink’s shares, and Li Li holds 99% of Shenzhen Leren Technology Co., Ltd.
Interestingly, through Tianyancha’s equity penetration, we learned that almost all of the ultimate controllers of Hai Purui are named “Li”. In addition to Li Li, there is also Li Tan. In addition, Shan Yu, a natural person, has a larger shareholding.
Hepalink’s financial report shows that Hepalink Li Li and Li Tan are husband and wife, and Shan Yu and Li Tan are brother and sister. Shan Yu participated in the company’s second phase of the employee stock ownership plan, and his participation share was 38.88% of the employee stock ownership plan in this period.
The company’s performance was poor, and the controlling shareholder had promised not to reduce its holdings for six months.
Media reports show that heparin is an anticoagulant drug extracted and processed from fresh, healthy pig intestines. It has multiple functions such as anticoagulation and antithrombosis. Heparin sodium API is mainly used to produce standard heparin preparations and low-molecular-weight heparin APIs, and then to produce low-molecular-weight heparin preparations.
According to Hepalink’s announcement, the company has two major heparin sodium API production bases, Hepalink and SPL. In addition to being partially supplied to its wholly-owned subsidiary Tiandao Medicine, heparin sodium API is mainly sold to foreign customers. The company’s cumulative export volume of enoxaparin sodium preparations Steadyly at the forefront of the country.
The company’s performance in the first three quarters of 2023 declined sharply.Screenshot of Hepalink announcement
However, this year, Hepalink’s performance was not good. The company’s third quarter report for 2023 showed that Hepalink’s revenue in the third quarter of 2023 was 1.35 billion yuan, a year-on-year decrease of 17.49%; the revenue in the first three quarters was 4.063 billion yuan, a year-on-year decrease of 24.69%. .
Hepalink’s net profit attributable to shareholders of listed companies in the third quarter of 2023 was 19.82 million yuan, a year-on-year decrease of 85.95%; the net profit in the first three quarters was 143 million yuan, a year-on-year decrease of 78.05%.
At the end of August 2023, the company issued an announcement stating that based on confidence in the company’s future development prospects and recognition of the company’s value, the company’s controlling shareholders voluntarily promised not to reduce or reduce their holdings in any way within six months starting from August 30, 2023. The transfer of company shares held includes shares generated from equity distributions such as bonus shares and transfer of reserve funds to share capital during the commitment period. During the commitment period, if there is a reduction in holdings in violation of the above commitments, all relevant proceeds from the reduction will belong to the company.